GGrantIndex
Sort

48,018 grants matching immunotherapy

Function of Wdfy4 in cross-presentation and immunity

$569,250
Kenneth M. Murphy · Washington University · R37 · FY2025 · AI

The Role of T Cell Avidity in Determining Tumor Immunity and Autoimmunity

$569,184
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA

Targeting GRP94-TGF-beta Pathway for Cancer Immunotherapy

$569,160
Zihai Li · Ohio State University · R01 · FY2021 · CA

The Role of T Cell Avidity in Determining Tumor Immunity and Autoimmunity

$569,136
Arthur Hurwitz · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA

Modulation of CSF1R Signaling to Treat Inflammatory Neuropathies

$569,135
Kazim A Sheikh · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · NS

Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model

$569,047
Ryan C Fields · Washington University · R01 · FY2024 · CA

UCLA Tumor Immunology Institutional Traning Grant

$569,019
Michael A Teitell · University Of California Los Angeles · T32 · FY2021 · CA

Viscoelasticity and T Cell Production

$568,911
David J Mooney · Harvard University · R01 · FY2023 · CA

Antigenic basis of immune responses after immune modulatory therapies post-HCT

$568,895
Catherine Ju-Ying Wu · Dana-Farber Cancer Inst · P01 · FY2023 · CA

SYNTHESIS OF CARBOHYDRATE IMMUNOSTIMULANTS

$568,882
Derek S Tan · Sloan-Kettering Inst Can Research · R01 · FY2010 · GM

Immunotherapy of low grade lymphoid malignancies

$568,871
Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2013 · HL

1 of 3 Interdisciplinary Collaboratory for Enhancing Translational Therapeutics Utilizing Biologically, Immunologically, and Metabollically Relevant Models of Breast Cancer

$568,802
William Joseph Murphy · University Of California At Davis · R01 · FY2016 · CA

Tumor and host immune signatures associated with patient outcomes to GD2 chemoimmunotherapy in neuroblastoma

$568,722
Kelly C Goldsmith · Emory University · R01 · FY2025 · CA

Induction of autosis to overcome resistance in adoptive cell therapy for solid tumors

$568,682
Yong Lu · Methodist Hospital Research Institute · R01 · FY2025 · CA

Release of interleukin-1a as a mediator of immune evasion in cancer

$568,538
Brian Ruffell · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2025 · CA

GENOMIC AND COMMENSAL VARIANTS ASSOCIATED WITH IMMUNOTHERAPY IN CANCER PATIENTS

$568,528
University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2017 · Department of the Army

Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplant

$568,505
Jarrod Dudakov · Fred Hutchinson Cancer Research Center · R01 · FY2020 · HL

Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplant

$568,505
Jarrod Dudakov · Fred Hutchinson Cancer Research Center · R01 · FY2021 · HL

Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplant

$568,505
Jarrod Dudakov · Fred Hutchinson Cancer Research Center · R01 · FY2019 · HL

Innate lymphoid cell regulation of the host-microbiota interactions in cancer

$568,491
Gregory F Sonnenberg · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA

Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.

$568,456
Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2019 · CA

Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy

$568,426
Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2020 · CA

Systematic interrogation of the pancreatic cancer microenvironment in patient-derived specimens

$568,413
William C Hahn · Dana-Farber Cancer Inst · U01 · FY2021 · CA

Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots

$568,324
Christopher M Jewell · Univ Of Maryland, College Park · R01 · FY2022 · AI

A Phase II Clinical Trial in Newly Diagnosed Glioblastoma Patients Treated with WP1066 and Radiation

$568,219
Amy Beth Heimberger · Northwestern University At Chicago · R01 · FY2024 · CA